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Aims To examine the diagnostic accuracy of sensitive cardiac troponin (cTn) assays in elderly patients, since elevated levels
with sensitive cTn assays were reported in 20% of elderly patients without acute myocardial infarction (AMI).
Methods
and results
In this multi-centre study, we included 1098 consecutive patients presenting with symptoms suggestive of AMI, 406
(37%) were .70 years old. Measurement of three investigational sensitive cTn assays [Roche high-sensitive cTnT
(hs-cTnT), Siemens cTnI-Ultra, and Abbott-Architect cTnI) and the standard assay (Roche cTnT) was performed
in a blinded fashion. The final diagnosis was adjudicated by two independent cardiologists. Acute myocardial infarction
was the adjudicated final diagnosis in 24% of elderly patients. Among elderly patients without AMI, baseline cTn levels
were elevated above the 99th percentile in 51% with Roche hs-cTnT, in 17% with Siemens TnI-Ultra, and 13% with
Abbott-Architect cTnI. The diagnostic accuracy as quantified by the area under the receiver operating characteristic
(ROC) curve (AUC) was significantly greater for the sensitive cTn assays compared with the standard assay (AUC for
Roche hs-cTnT, 0.94; Siemens cTnI-Ultra, 0.95; and Abbott-Architect cTnI, 0.95 vs. AUC for the standard assay, 0.90;
P, 0.05 for comparisons). The best cut-offs for the sensitive cTn-assays determined by the ROC-curve in elderly
patients differed clearly from those in younger patients. Furthermore, the prognostic value regarding 90-day mortality
varied among the sensitive cTn assays.
Conclusion Sensitive cTn assays have high diagnostic accuracy also in the elderly. Mild elevations are common in elderly non-AMI
patients, therefore the optimal cut-off levels are substantially higher in elderly as compared with younger patients.
Furthermore, sensitive cTn assays yielded different prognostic value (ClinicalTrials.gov number, NCT00470587).
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Introduction
Acute myocardial infarction (AMI) is the leading cause of death and
morbidity in the elderly population of Europe and the USA.1 Its
rapid and accurate diagnosis is an unmet clinical need. Delayed
‘rule in’ increases morbidity and mortality.2,3 Delayed ‘rule out’
prolongs the time spent in the emergency department (ED),
increasing patients’ anxiety and causes enormous costs for the
health-care system.4
New sensitive cardiac troponin (cTn) assays, with a lower limit
of detection (LoD), below the 99th percentile of a normal
reference population, have recently become available in clinical
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practice.5,6 These assays improved the early diagnosis of an AMI in
unselected patients with acute chest pain.7,8 However, their diag-
nostic accuracy in the elderly is uncertain, as elevated levels of
cTn were found in up to 22% of persons living in the community
who were 70 years of age or older.9 –11
Therefore, and for other reasons, elderly patients merit particu-
lar attention. First, pre-existing heart diseases, risk factors, as well
as diseases that potentially cause AMI-like chest pain such as gas-
tritis or pneumonia are more common in the elderly.12–14 Thus,
they are at increased risk for both: AMI, as well as anxiety
related to non-cardiac causes of chest pain. Secondly, the
interpretation of the 12-lead electrocardiography (ECG) is particu-
larly challenging in elderly patients due to common pre-existing
ECG alterations such as a bundle branch block or a pacemaker.
In contrast, new ST-segment-elevation is less common in the
elderly compared with younger patients.15 Thirdly, the diagnosis
of an AMI is even more challenging in the elderly since they
differ from younger patients in perception and presentation of
the symptoms.16,17 Fourthly, due to frequently pre-existing heart
diseases and renal failure, cTn levels may also be elevated in
elderly patients without an AMI.18,19 Fifthly, the elderly are more
prone to adverse events related to cardiovascular medication,
e.g. anticoagulation, as well as to cardiovascular procedures, e.g.
coronary angiography, and percutaneous coronary intervention.
In this context, an accurate diagnosis of an AMI is mandatory for
therapeutic indications.20– 22
We therefore examined the diagnostic performance of novel
sensitive cTn assays for the early diagnosis of an AMI in patients
.70 years of age, presenting with acute chest pain to the ED.
Methods
Study design and population
The Advantageous Predictors of Acute Coronary Syndrome Evaluation
(APACE) Study is an ongoing prospective international multi-centre
study designed and co-ordinated by the University Hospital Basel.
From April 2006 to June 2009, a total of 1247 consecutive patients
presenting to the ED with symptoms suggestive of an AMI with an
onset or peak within the last 12 h were recruited. Elderly patients
were considered those .70 years of age.
The study was carried out according to the principles of the
Declaration of Helsinki and approved by the local Ethics Committees.
Written informed consent was obtained from all patients. The authors
designed the study, gathered, and analysed the data, vouch for the data
and analysis, wrote the paper, and made the decision to submit it for
publication. The assays were donated by the manufacturers, who had
no role in the design of the study, the analysis of the data, the prep-
aration of the manuscript, or the decision to submit for publication.
Routine clinical assessment
All patients underwent an initial clinical assessment that included
history taking, a physical examination, 12-lead ECG, continuous ECG
monitoring, pulse oximetry, standard blood tests, and chest radiogra-
phy. Cardiac troponin I or cTnT, CK-MB, and myoglobin were
measured at presentation and 6–9 h after presentation or as long as
clinically indicated. The precise timing of clinical post-baseline
measurements and the treatment of patients were left to the discre-
tion of the attending physician.
Adjudicated final diagnosis
To determine the final diagnosis for each patient, two independent car-
diologists reviewed all available medical records—the clinical history,
findings on physical examination, and results of laboratory tests
(including cTn values obtained at the participating hospitals but not
those being assessed as part of this study), radiologic testing, ECG,
echocardiography, cardiac exercise test, coronary angiography—from
the time of the patient’s arrival in the ED to the end of the 90-day
follow-up period. When there was disagreement about the diagnosis,
cases were reviewed and adjudicated in conjunction with a third
cardiologist.
An AMI was defined in accordance with current guidelines.23 In
brief, an AMI was diagnosed when there was evidence of myocardial
necrosis in association with clinical signs of myocardial ischaemia.
Necrosis was diagnosed by a rising and/or falling pattern of the local
cTn level, with at least one value above the 99th percentile, at a
level of imprecision of ,10%.5 The following cTn assays were used
for the adjudication of the final diagnosis at the participating hospitals:
Abbott Axsym cTnI ADV, Beckmann Coulter Accu cTnI, and Roche
cTnT. All three are well-validated current cTn assays with comparable
performance in the diagnosis of an AMI.5 Unstable angina was diag-
nosed when a patient had normal cTn levels but new onset or a
deterioration of stable angina, positive cardiac exercise testing, coron-
ary artery stenosis of 70% in subsequent cardiac catheterization.
Unstable angina was also diagnosed when the diagnosis during hospi-
talization was uncertain but AMI or sudden cardiac death within 90
days occurred, that was evidently associated with the symptoms
described at prior presentation. Further pre-defined diagnostic cat-
egories were cardiac but not coronary symptoms (e.g. perimyocarditis
or tachyarrhythmias), and non-cardiac causes. If AMI was ruled out at
presentation, but no sufficient diagnostic procedures were performed
during follow up to establish a definite final diagnosis, symptoms were
classified as chest pain of unknown origin.
Investigational cardiac troponin analysis
Blood samples for determination of four investigational cTn assays
(three sensitive: Roche High-Sensitive-cTnT, Siemens cTnI-Ultra,6,24
Abbott cTnI-Architect, and one standard: Roche cTnT25) were col-
lected at the time of the patient’s presentation to the ED. Additional
samples were collected at 1, 2, 3, and 6 h. Serial sampling was discon-
tinued when the diagnosis of an AMI was certain and treatment
required transferring the patient to the catheter laboratory or coron-
ary care unit. After centrifugation, samples were frozen at 2808C until
they were assayed in a blinded fashion in two batches in a dedicated
core laboratory.
The two Roche assays were performed with the use of the Elecsys
2010 system (Roche Diagnostics): for cTnT (fourth generation), the
LoD is 0.01 mg/L, the 99th percentile ,0.01 mg/L, and the coefficient
of variation of ,10% (10% CV) is 0.035 mg/L; for hs-cTnT, the LoD is
0.005 mg/L, the 99th percentile 0.014 mg/L, and the 10% CV is
0.013 mg/L.26 For the Siemens cTnI-Ultra assay, performed with the
ADVIA Centaur immunoassay system (Siemens), the LoD is 0.006 mg/
L, the 99th percentile 0.04 mg/L, and the 10% CV is 0.03 mg/L, as
specified by the manufacturer.6,7,24 For the Abbott-Architect cTnI
assay, performed with the Architect system (Abbott Diagnostics), the
LoD is 0.01 mg/L, the 99th percentile 0.028 mg/L, and the 10% CV is
0.032 mg/L, as specified by the manufacturer.
Statistical analysis
Continuous variables are presented as means (+SD) or medians [with
the inter-quartile range (IQR)], and categorical variables as numbers
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and percentages. Continuous variables were compared with the use of
the Mann–Whitney test and categorical variables with the use of the
Pearson x2 test. Receiver operating characteristic (ROC) curves
were constructed to assess the sensitivity and specificity of cTn
measurements obtained at specific times with the four assays and to
compare their ability to diagnose an AMI. Logistic regression was
used to combine cTn levels at presentation with early changes in
cTn levels. The comparison of areas under the ROC curves (AUC)
was performed as recommended by DeLong et al.27 The best cut-off
values were determined by the point farthest from the bisector of
the ROC curve. For the analysis of the prognostic value of the sensitive
cTn assays, we calculated Kaplan–Meier curves, using the log-rank test
for comparisons and Cox regression. All hypothesis testing was two-
tailed, and P-values of ,0.05 were considered to indicate statistical sig-
nificance. All statistical analyses were performed with the use of SPSS
for Windows, version 15.0 (SPSS), and MedCalc software, version
10.3.0 (MedCalc).
Results
Patient characteristics
Of the 1247 consecutively enrolled patients, measurement of all
four investigational cTn assays were obtained at presentation
from 1098 patients, of whom 406 (37%) were older than 70
years. Elderly patients differed from those younger than 70 years
of age in several of the baseline characteristics (Table 1). The
90-day follow-up was completed in 100% of patients.
Acute myocardial infarction was the adjudicated final diagnosis in
24% of patients over 70 years when compared with 9% in younger
patients (P, 0.001). Other adjudicated diagnoses were unstable
angina in 16%, cardiac symptoms from causes other than coronary
artery disease in 15%, non-cardiac causes in 34%, and symptoms of
unknown origin in 11% of the elderly patients (Table 2).
Cardiac troponin levels at presentation
Among the patients, whose final diagnosis was not an AMI, patients
over 70 years old had significantly higher baseline levels of all three
sensitive cTn compared with younger patients: median levels in
patients aged ≥70 were 0.014 mg/L (IQR: 0.009–0.024), with
hs-cTnT; 0.01 mg/L (IQR: 0.004–0.025), with cTnI-Ultra; and
0.003 mg/L (IQR: 0–0.011), with Abbott-Architect cTnI; compared
with 0.005 mg/L (IQR: 0.003–0.009), with hs-cTnT; 0.004 mg/L
(IQR: 0.001–0.011), with cTnI-Ultra; and 0.000 mg/L (IQR:
0.000–0.002) with Abbott-Architect cTnI in younger patients
(P, 0.001 for comparisons). Of the total, 51% of the elderly
patients with a final diagnosis other than AMI, had elevated base-
line levels of hs-cTnT, 17% had elevated baseline levels of the
Siemens cTnI-Ultra, and 13% had elevated baseline levels of
Abbott-Architect cTnI above the 99th percentile. Among
younger patients, the percentages were significantly smaller with
the sensitive cTn assays (14, 8, and 7%; P, 0.001, P ¼ 0.002,
and P ¼ 0.004, respectively; Figure 1).
In elderly as well as in younger patients, cTn levels at presen-
tation, as assessed by all the assays, were significantly higher in
patients whose final diagnosis was AMI when compared with
those with other diagnoses (P, 0.001 for comparisons).
Diagnostic accuracy of cardiac troponin at
presentation
In elderly patients, the diagnostic accuracy for an AMI, quantified
by the AUC, was significantly higher with the three sensitive cTn
assays than that with the standard assay [AUC for Roche
hs-cTnT: 0.94; 95% confidence interval (CI): 0.91–0.96; for
Siemens cTnI-Ultra: 0.95; 95% CI: 0.93–0.97; and for
Abbott-Architect cTnI: 0.95; 95% CI: 0.92–0.97; vs. AUC for the
standard assay: 0.90; 95% CI: 0.87–0.93; P ¼ 0.015, P ¼ 0.003,
P ¼ 0.006, respectively, for comparisons; Table 3 and Figure 2A].
Overall, among all three sensitive assays, the diagnostic accuracy
was similar (P . 0.05). In younger patients, the diagnostic accuracy
for an AMI was also significantly higher with the sensitive assays
than that with the standard assay (AUC for Roche hs-cTnT:
0.94; 95% CI: 0.91–0.96; for Siemens cTnI-Ultra: 0.95; 95% CI:
0.93–0.97; and for Abbott-Architect cTnI: 0.95; 95% CI: 0.92–
0.97; vs. AUC for the standard assay: 0.90; 95% CI: 0.87–0.93;
P ¼ 0.015, P ¼ 0.003, P ¼ 0.006, respectively, for comparisons;
Table 2 and Figure 2C). Overall, comparing the AUC of the three
sensitive assays in elderly vs. younger patients, we found no signifi-
cant differences (P. 0.4 for all tests).
Best cut-off determined by receiver
operating characteristic curve
The best cut-off value to separate AMIs from non-AMIs deter-
mined by ROC analysis in elderly patients was nearly four times
the 99th percentile for hs-cTnT (0.054 mg/L), but close to the
99th percentile for both sensitive cTnI assays (0.032 mg/L for
Abbott-Architect cTnI and 0.045 mg/L for Siemens cTnI-Ultra;
see Table 4 and Figure 2A).
In contrast, the best cut-off value to separate AMIs from
non-AMIs in younger patients was close to the 99th percentile
for hs-cTnT (0.017 mg/L) and for cTnI-Ultra (0.039 mg/L), but
less than a third of the 99th percentile for Abbott-Architect cTnI
(0.008 mg/L; see Table 5 and Figure 2C).
Cardiac troponin levels in patients with
recent onset of chest pain
The accuracy of the sensitive cTn assays was also high among
patients with recent onset of chest pain (Figure 2B and D,
Figure 3, and Supplementary material online, Table S5A).
Diagnostic performance at the 99th
percentile in elderly and younger patients
Overall, at the 99th percentile all cTn assays showed higher sensi-
tivity in elderly when compared with younger patients. The
increase in sensitivity in elderly patients was associated with a
decrease in specificity, which was particularly pronounced with
hs-cTnT (49% in the elderly vs. 86% in younger patients; P,
0.001; see Table 6).
Serial cardiac troponin levels
During serial sampling, the AUC for all cTn assays increased in
patients over 70 years (Supplementary material online, Table
S5B). Absolute values of changes in cTn levels from presentation
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Table 1 Baseline characteristics
All patients Patients >70 years Patients ≤ 70 years P-value* Patients >70 years
(n5 1098) (n 5 406) (n 5 681) Acute myocardial infarction P-value
Yes (n5 98) No (n5 308)
Male gender, n (%) 756 (67) 218 (54) 511 (75) ,0.001 63 (64) 155 (50) 0.016
Age (years)
Median 64 (51–75) 78 (74–82) 54 (46–63) ,0.001 79 (75–85) 78 (74–85) 0.093
Risk factors, n (%)
Hypertension 693 (63) 330 (81) 360 (53) ,0.001 83 (85) 247 (80) 0.320
Dyslipidaemia 492 (45) 210 (52) 282 (41) 0.001 52 (53) 158 (51) 0.761
Diabetes 217 (20) 110 (27) 107 (16) ,0.001 31 (32) 79 (26) 0.244
Current smoking 265 (24) 36 (9) 224 (33) ,0.001 12 (12) 24 (8) 0.179
Prior smoking 391 (36) 154 (38) 236 (35) 0.235 39 (40) 115 (37) 0.675
History, n (%)
Prior coronary artery disease 401 (37) 212 (52) 189 (27) ,0.001 56 (57) 156 (51) 0.262
Prior myocardial infarction 271 (25) 146 (36) 125 (18) ,0.001 42 (43) 104 (34) 0.102
Prior revascularization 296 (27) 140 (35) 155 (23) ,0.001 33 (34) 107 (35) 0.847
PCI 254 (23) 116 (29) 137 (20) 0.001 24 (25) 92 (30) 0.304
Surgery 111 (10) 68 (17) 43 (6) ,0.001 18 (18) 50 (16) 0.622
Peripheral artery disease 76 (7) 53 (13) 23 (3) ,0.001 13 (13) 40 (13) 0.943
Impaired kidney function 115 (11) 90 (22) 25 (4) ,0.001 28 (29) 62 (20) 0.080
Prior stroke 64 (6) 51 (13) 13 (2) ,0.001 17 (17) 34 (11) 0.101
All patients Patients >70 years Patients ≤70 years P-value* Patients >70 years
(n5 1098) (n 5 406) (n 5 692) Acute Myocardial Infarction P-value
Yes (n5 98) No (n 5 308)
Vital status, median (IQR)
Heart rate (b.p.m.) 75 (66–89) 75 (64–90) 76 (66–89) 0.086 81 (71–100) 73 (62–88) ,0.001
Systolic blood pressure (mmHg) 142 (127–160) 145 (127–164) 142 (127–158) 0.097 136 (119–161) 146 (130–164) 0.011
Continued
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to 1 and 2 h had similar diagnostic accuracy as the baseline cTn
levels. The combination of baseline levels plus early changes did
slightly improve the performance of the baseline level for all cTn
assays. This increase in accuracy was statistically significant for
the hs-cTnT assay and the Siemens cTnI-Ultra assay with the com-
bination of the baseline levels and the change already within the
first hour after presentation (P ¼ 0.013 and P ¼ 0.017, respect-
ively). For the Abbott-Architect cTnI assay, the improvement in
accuracy was only significant with the combination of the baseline
level and the change within the first 2 h after presentation (P ¼
0.014; Supplementary material online, Table S5C). The diagnostic
performance of the standard cTn was significantly improved by
the measurement of early changes in cTn levels after 2 h as well
as by the combination of baseline levels plus early changes at 1 h
and at 2 h (P, 0.05; see Supplementary material online, Table
S5C).
Cardiac troponin in the diagnosis of
unstable angina and acute coronary
syndromes
In elderly patients, the sensitive cTn assays had very poor accuracy
for differentiating unstable angina from non-cardiac causes of chest
pain (AUC for Roche hs-cTnT: 0.62; 95% CI: 0.55–0.69; for
Siemens cTnI-Ultra: 0.58; 95% CI: 0.51–0.65; for Abbott-Architect
cTnI: 0.59; 95% CI: 0.52–0.66). The diagnostic accuracy for differ-
entiating unstable angina from non-cardiac causes of chest pain was
significantly higher in younger patients than in elderly with Roche
hs-cTnT (AUC: 0.74; 95% CI: 0.69–0.80; P ¼ 0.019 for compari-
son). Within the group of younger patients and within the group
of elderly patients the diagnostic accuracy of all sensitive cTn
assays was similarly low (P . 0.2 for comparisons). However, the
diagnostic performance among sensitive assays was still significantly
greater than that of the standard assay (AUC for the standard assay
0.52 in elderly as well as in younger patients, P, 0.001 for com-
parisons of the standard assay with the sensitive assays among
elderly and younger patients).
In elderly patients, for the diagnosis of acute coronary syn-
dromes (AMI or unstable angina), the negative-predictive value
of a negative assay result, defined as a value below the 99th per-
centile with a level of imprecision of ,10%, was 64% (57–71%)
for Roche hs-TnT, 65% (60–71%) for Siemens cTnI-Ultra, 64%
(58–70%) for Abbott-Architect cTnI, and 61% (56–66%) for the
standard assay. In younger patients, the negative-predictive value
was 86% (83–89%), 86% (82–88%), 84% (81–87%), and 82%
(78–85%), respectively.
Prognostic value of sensitive cardiac
troponin assays
The 90-day follow-up was completed in 100% of patients. Elevated
levels of hs-cTnT and Siemens cTnI-Ultra above the 99th percen-
tile at presentation in patients who had a final diagnosis other than
AMI strongly predicted death within 90 days, while elevated levels
of Abbott-Architect cTnI had no predictive value (Figure 4).
Accordingly, in a Cox regression model, adjusted for age .70
years, hs-cTnT, and Siemens TnI-Ultra levels above the 99th per-
centile represented independent predictors for death within 90
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days among patients whose final diagnosis was other than AMI
(HR: 4.7; 95% CI: 1.2–18.6; P ¼ 0.027 for Roche hs-cTnT; and
HR: 3.6; 95% CI: 1.2–11.0; P ¼ 0.027 for Siemens cTnI-Ultra).
Regarding AMI within 90 days, none of the sensitive cTn assays
had predictive value (all P . 0.05).
Discussion
This prospective multi-centre study involving consecutive patients
.70 years of age examined the diagnostic performance of new
sensitive cTn assays for the early diagnosis of AMI. We report
seven major findings that have important clinical implications for
‘rule in’ and ‘rule out’ AMI:
First, among elderly patients with a final diagnosis other than
AMI, the percentage of patients with a baseline level of sensitive
cTnI and hs-cTnT above the 99th percentile was high and differed
largely among the three sensitive cTn assays, ranging from 13 to
51%. Clinically, the high incidence of elevated cTn levels in the
elderly challenges the application of the 99th percentile as the
decision limit for the diagnosis of AMI as suggested in current
guidelines. Careful clinical assessment is essential to separate
AMIs from a variety of acute and chronic disorders also associated
with low-level myocardial necrosis, especially in elderly patients,
since rhythm disorders, heart failure, and impaired renal function
are common in them.19
In addition, the substantial difference between the sensitive cTnI
assays and the hs-TnT assay, regarding the incidence of cTn levels
above the 99th percentile in patients without AMI, might indicate a
variation of release of cTnI and cTnT in these non-AMI settings.
The hypothesis of a difference in the release between cTnI and
cTnT is supported by recent data indicating a higher prevalence
of hs-cTnT levels above the 99th percentile than of cTnI levels
above the 99th percentile in elderly patients without symptoms
or signs of AMI.9,10
Secondly, despite the above findings, the diagnostic accuracy was
similarly high already at presentation for all three sensitive cTn
assays in elderly (AUC: 0.94–0.95) as well as in younger patients
(AUC: 0.94–0.96) and significantly higher than that of the standard
assay.
Thirdly, although the AUC of sensitive cTn assays did not differ
significantly comparing elderly and younger patients, the best
cut-off values to separate AMIs from non-AMIs varied substantially.
Among elderly patients, the best cut-off values to separate AMIs
from non-AMIs were around the 99th percentile with the sensitive
cTnI assays, but nearly four times the 99th percentile with hs-cTnT.
In contrast, the best cut-off values in younger patients were close
to the 99th percentile for hs-cTnT and for cTnI-Ultra, but less than
a third of the 99th percentile for Abbott-Architect cTnI. These
findings highlight the clinical need to develop test-specific algor-
ithms that fine tune the application of these novel tests for the
diagnosis of patients with acute chest pain.9,11
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Table 2 Final diagnoses, n (%)
All patients Patients >70 years Patients ≤70 years P-value*
(n5 1098) (n5 406) (n5 692)
Acute myocardial infarction 173 (16) 98 (24) 75 (11) <0.001
ST-segment-elevation 41 (4) 21 (5) 20 (3) 0.054
Non-ST-segment-elevation 132 (12) 77 (19) 55 (8) <0.001
Unstable angina 152 (14) 66 (16) 86 (12) 0.076
Cardiac cause, but not CAD 146 (13) 59 (15) 88 (13) 0.394
Non-cardiac cause 518 (48) 140 (34) 388 (56) <0.001
Unknown 98 (9) 43 (11) 55 (8) 0.138
*Comparison of patients .70 years and ≤70 years.
Figure 1 Baseline levels of sensitive troponin at presentation.
Troponin levels at presentation to the emergency department
displayed as multiples of the 99th percentile in patients whose
adjudicated final diagnosis was other than acute myocardial
infarction. Boxes represent inter-quartile ranges, while whiskers
display ranges (without outliers further than 1.5 inter-quartile
ranges from the end of the box). Left side: patients, .70 years
of age. Right side: patients, age 70 years or younger.
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Fourthly, the accuracy of sensitive cTn assays was also very high
among elderly patients with a recent onset of chest pain. Improve-
ment in the early diagnosis of AMI offers the opportunity to mini-
mize myocardial damage by extending early treatment options to
AMI patients without ST-segment-elevation.1,2 Our findings high-
light that the ‘rule in’ benefits of sensitive cTn assays can be con-
firmed in the high-risk group of elderly patients.1,2,23 The cost
savings associated with increased sensitivity already at presentation
might be substantial.4 On the other hand, the lower specificity
increases the incidence of patients with elevated cTn levels not
having an AMI, which may trigger additional costly investigations
to identify the cause of myocardial necrosis. Detailed cost analyses
need to be performed to define the net economic effect of the
clinical application of the sensitive cTn assays.28
Furthermore, the distinction between an AMI and other medical
conditions associated with cTn elevations including myocarditis,
tako-tsubo cardiomyopathy, and heart failure will still require full
clinical evaluation. Also, the ECG remains an indispensable tool
to immediately identify patients with ST-segment-elevation
AMI.2– 6
Fifthly, the overall diagnostic accuracy of the sensitive assays at
the 99th percentile, quantified by the AUC for the sensitive
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Table 3 Diagnostic performance of cardiac troponin in elderly patients at presentation (n5 406)
Sensitivity
(95% CI)
Specificity
(95% CI)
Negative-predictive
value (95% CI)
Positive-predictive
value (95% CI)
Sensitive troponin assays
Roche high-sensitive troponin T
Limit of detection (0.005 mg/L) 100 (96–100) 1 (0–3) 100 (40–100) 24 (20–29)
99th percentile (0.014 mg/L)a 98 (93–100) 49 (44–55) 99 (95–100) 38 (32–44)
Siemens troponin I-Ultra
Limit of detection (0.006 mg/L) 99 (94–100) 30 (25–35) 99 (94–100) 31 (26–36)
99th percentile (0.040 mg/L)a 92 (85–96) 83 (79–87) 97 (94–99) 64 (55–72)
Abbott-architect troponin I
Limit of detection (0.010 mg/L) 94 (87–98) 72 (67–78) 97 (94–99) 52 (45–60)
99th percentile (0.028 mg/L) 89 (81–94) 87 (83–91) 96 (93–98) 69 (60–77)
10% CV (0.032 mg/L) 88 (80–94) 88 (84–92) 96 (93–98) 70 (62–78)
Standard troponin assay
Roche troponin T fourth generation
99th percentile (unknown)
Limit of detection (0.010 mg/L) 83 (74–90) 90 (86–93) 94 (91–97) 72 (62–80)
10% CV (0.035 mg/L) 76 (57–79) 96 (93–98) 93 (89–95) 86 (77–93)
aCriterion of 10% variation coefficient (10% CV) fulfilled at the 99th percentile.
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Table 4 Diagnostic performance of sensitive troponin assays in elderly patients (>70 years old) at the best cut-off
determined by the receiver operating characteristic curve (95% confidence interval)
Best cut-off ROC Best cut-off ROC 99th percentile P-value*
Sensitive troponin assays
Roche high-sensitive troponin T,
99th percentile (0.014 mg/L)
0.054 mg/L Sensitivity 79 (69–86) 98 (92–100) <0.001
Specificity 96 (93–98) 49 (44–55) <0.001
Negative-predictive value 93 (90–96) 99 (95–100) 0.042
Positive-predictive value 86 (77–92) 38 (32–44) <0.001
Siemens troponin I-Ultra, 99th
percentile (0.040 mg/L)
0.045 mg/L Sensitivity 92 (85–96) 92 (85–96) 1
Specificity 88 (84–91) 83 (79–87) 0.458
Negative-predictive value 97 (94–99) 97 (94–99) 0.997
Positive-predictive value 71 (62–79) 64 (55–72) 0.643
Abbott-Architect Troponin I,
99th percentile (0.028 mg/L)
0.032 mg/L Sensitivity 88 (80–94) 89 (81–94) 0.976
Specificity 88 (84–91) 87 (83–91) 0.934
Negative-predictive value 96 (93–98) 96 (93–98) 0.984
Positive-predictive value 70 (62 –78) 69 (60–77) 0.970
*Comparisons among elderly patients.
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assays did not differ significantly in elderly and younger patients.
However, regarding the diagnostic parameters in detail, the sensi-
tivity and specificity of the sensitive cTn assays diverged in the
elderly compared with younger patients, especially with hs-TnT.
All cTn assays showed higher sensitivity but lower specificity in
elderly when compared with younger patients, reflecting the
higher incidence of baseline levels above the 99th percentile in
elderly patients with a final diagnosis other than AMI.
Figure 2 Diagnostic performance of cardiac troponin at presentation. Receiver operating characteristic curves describing the diagnostic per-
formance of different cardiac troponin assays at presentation for the diagnosis of acute myocardial infarction in patients .70 years of age (top),
and in those, aged 70 years or younger (bottom). Left side: presenting within 12 h from chest pain onset. Right side: presenting within ,3 h of
chest pain onset. (A and C): the calculated best cut-off values for elderly and for younger patients are defined by the point farthest from the
bisector of the receiver operating characteristic curves.
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Table 5 Diagnostic performance of sensitive troponin assays in younger patients (70 years or younger) at the best
cut-off determined by the receiver operating characteristic curve (95% confidence interval)
Best cut-off ROC Best cut-off ROC 99th percentile P-value*
Sensitive troponin assays
Roche high-sensitive troponin T,
99th percentile (0.014 mg/L)
0.017 mg/L Sensitivity 88 (78–94) 88 (78–94) 1
Specificity 90 (87–92) 86 (83–89) 0.215
Negative-predictive value 98 (97–99) 98 (97–99) 0.997
Positive-predictive value 51 (42–60) 44 (36–52) 0.527
Siemens troponin I-Ultra, 99th
percentile (0.040 mg/L)
0.039 mg/L Sensitivity 87 (77–93) 87 (77–93) 1
Specificity 92 (90–94) 92 (89–94) 0.979
Negative-predictive value 98 (97–99) 98 (97–99) 1
Positive-predictive value 57 (47–66) 56 (47–72) 0.989
Abbott-Architect troponin I,
99th percentile (0.028 mg/l)
0.008 mg/L Sensitivity 91 (82–96) 79 (68–87) 0.125
Specificity 85 (82–88) 93 (91–95) <0.001
Negative-predictive value 99 (97–99) 97 (96–98) 0.256
Positive-predictive value 43 (35–51) 57 (47–67) 0.065
*Comparisons among younger patients.
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Sixthly, sensitive cTn assays seemed not helpful in the diagnosis
of unstable angina in elderly patients and had only little value in
younger patients. Further research is necessary to identify bio-
markers that reliably detect myocardial ischaemia without
necrosis.8,29
Seventhly, elevated levels of Roche hs-cTnT and Siemens TnI
Ultra in patients with a final diagnosis other than AMI were
strongly related to all-cause mortality within 90 days. This associ-
ation was not seen for the Abbott-Architect cTnI. Further investi-
gations are required to specify the prognostic capabilities of
sensitive cTn assays for short- and long-term prognosis and to illu-
minate potential explanations for differences among sensitive cTn
assays and outcomes. Our findings extend the results of previous
studies, investigating the long-term mortality of apparently
healthy subjects with elevated levels measured with sensitive
cTnI assays.11,30 Further, we found that none of the sensitive
cTnI assays predicted an AMI within 90 days.11,30
The following limitations of the current study merit consider-
ation. First, we evaluated three sensitive cTn assays. We hypoth-
esize that our findings can be generalized to other cTn assays
with similar sensitivity and precision. However, additional studies
need to confirm this hypothesis. Secondly, in this ongoing prospec-
tive study, the subgroup analysis of patients aged .70 years was
not pre-defined at the time of the initial protocol written in
2005. It was added while we were still blinded to the results in
2008,8 with regard to recent investigations, showing that up to
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Table 6 Diagnostic performance of sensitive troponin assays at the 99th percentile; at 10% coefficient of variation for
the standard assay (95% confidence interval)
>70 years ≤70 years P-value*
Sensitive troponin assays
Roche high-sensitive troponin T,
99th percentile (0.014 mg/L)
Sensitivity 98 (92–100) 88 (78–94) 0.019
Specificity 49 (44–55) 86 (83–89) <0.001
Negative-predictive value 99 (95–100) 98 (97–99) 0.984
Positive-predictive value 38 (32–44) 44 (36–52) 0.288
Siemens troponin I-Ultra, 99th
percentile (0.040 mg/L)
Sensitivity 92 (85–96) 87 (77–93) 0.394
Specificity 83 (79–87) 92 (89–94) <0.001
Negative-predictive value 97 (94–99) 98 (97–99) 0.370
Positive-predictive value 64 (55–72) 56 (47–65) 0.253
Abbott-Architect troponin I,
99th percentile (0.028 mg/L)
Sensitivity 89 (81–94) 79 (68–87) 0.109
Specificity 87 (83–91) 93 (91–95) 0.008
Negative-predictive value 96 (93–98) 97 (96–98) 0.481
Positive-predictive value 69 (60–77) 57 (47–67) 0.088
Standard troponin assay
Roche troponin T fourth
generation, 99th percentile
(unknown) 10% CV (0.035 mg/L)
Sensitivity 76 (57–79) 59 (47–70) 0.028
Specificity 96 (93–98) 98 (97–99) 0.135
Negative-predictive value 93 (89–95) 95 (93–97) 0.152
Positive-predictive value 86 (77–93) 79 (66–88) 0.351
*Comparison of patients .70 years and ≤70 years.
Figure 3 Diagnostic accuracy at presentation according to chest pain onset. Area under the receiver operating characteristic curves for the
different cardiac troponin assays at presentation in the diagnosis of acute myocardial infarction according to the time since chest pain onset. (A):
patients, .70 years of age. (B): patients, age 70 years or younger.
Sensitive troponins for the early diagnosis of AMI 1387
21% of elderly, presumably healthy patients had elevated levels of
sensitive cTn.9 –11 Thirdly, this observational study cannot quantify
exactly the clinical benefit associated with the increase in early
diagnostic accuracy. To add this important information, interven-
tional studies seem warranted. Fourthly, some of the patients
with positive sensitive cTn values classified as non-AMIs might
have had small AMIs below the decision value of conventional
cTn. Presumably, this contributed to the reduced specificity of
the sensitive assays. Fifthly, in this study, we found discrepant
prognostic performance among the sensitive cTnI assays. Further
analyses are necessary to evaluate possible explanations for
these differences.
In conclusion, the excellent diagnostic performance of sensitive
cTn assays in the early diagnosis of AMI can be confirmed in elderly
as well as in younger patients. However, elevated cTn levels are
common in elderly patients with diagnoses other than AMI and
challenge differential diagnoses and currently recommended
cut-off levels in the elderly, particularly with hs-cTnT, highlighting
the clinical need to develop test-specific algorithms for patients
with acute chest pain.
Supplementary material
Supplementary material is available at European Heart Journal
online.
Acknowledgements
We are indebted to the patients who participated in the study and
to the ED staff as well as the laboratory technicians for their most
valuable efforts, and we thank Dr. C. Schindler for expert statistical
advice.
Funding
The study was supported by research grants from the Swiss National
Science Foundation (PP00B-102853), the Swiss Heart Foundation,
Abbott, Roche, Siemens, and the Department of Internal Medicine,
University Hospital Basel.
We disclose that C.M. has received research support from the Swiss
National Science Foundation (PP00B-102853), the Swiss Heart Foun-
dation, the Novartis Foundation, the Krokus Foundation, Abbott,
Astra Zeneca, Biosite, Brahms, Nanosphere, Roche, Siemens, and the
Department of Internal Medicine, University Hospital Basel, as well
as speaker honoraria from Abbott, Biosite, Brahms, Roche, and
Siemens.
Conflict of interest: none declared.
References
1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr,
Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED,
Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL,
Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP,
Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients
with unstable angina/non ST-elevation myocardial infarction: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the
Management of Patients With Unstable Angina/Non ST-Elevation Myocardial
Infarction): developed in collaboration with the American College of Emergency
Physicians, the Society for Cardiovascular Angiography and Interventions, and the
Society of Thoracic Surgeons: endorsed by the American Association of Cardio-
vascular and Pulmonary Rehabilitation and the Society for Academic Emergency
Medicine. Circulation 2007;116:e148–e304.
2. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F,
Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis
and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart
J 2007;28:1598–1660.
3. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G,
Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable
angina/non-ST elevation MI: a method for prognostication and therapeutic
decision making. JAMA 2000;284:835–842.
4. Forberg JL, Henriksen LS, Edenbrandt L, Ekelund U. Direct hospital costs of chest
pain patients attending the emergency department: a retrospective study. BMC
Emerg Med 2006;6:6.
Figure 4 Prognostic impact of elevations in cardiac troponin in
patients with final diagnosis other than acute myocardial infarc-
tion. Kaplan–Meier curves showing mortality within 90 days in
patients whose final diagnosis was other than acute myocardial
infarction, comparing patients with levels of sensitive troponins
above (green lines) and below (blue lines) the 99th percentile.
M. Reiter et al.1388
5. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of
Clinical Biochemistry and IFCC Committee for Standardization of Markers of
Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for
biochemical markers of acute coronary syndromes. Circulation 2007;115:
e352–e355.
6. Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM. Use of the Centaur
TnI-Ultra assay for detection of myocardial infarction and adverse events in
patients presenting with symptoms suggestive of acute coronary syndrome. Clin
Chem 2008;54:723–728.
7. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S,
Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB,
Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ,
Munzel TF, Blankenberg S. Sensitive troponin I assay in early diagnosis of acute
myocardial infarction. N Engl J Med 2009;361:868–877.
8. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S,
Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R,
Winkler K, Bingisser R, Mueller C. Early diagnosis of myocardial infarction with
sensitive cardiac troponin assays. N Engl J Med 2009;361:858–867.
9. Eggers KM, Lind L, Ahlstrom H, Bjerner T, Ebeling Barbier C, Larsson A, Venge P,
Lindahl B. Prevalence and pathophysiological mechanisms of elevated cardiac tro-
ponin I levels in a population-based sample of elderly subjects. Eur Heart J 2008;
29:2252–2258.
10. Eggers KM, Lind L, Venge P, Lindahl B. Will the universal definition of myocardial
infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol
2009;103:588–591.
11. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart
disease and mortality in 70-year-old men: a community-based cohort study. Circu-
lation 2006;113:1071–1078.
12. Faisal MA, Russell RM, Samloff IM, Holt PR. Helicobacter pylori infection and
atrophic gastritis in the elderly. Gastroenterology 1990;99:1543–1544.
13. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH,
Gottdiener J, Fried LP. Frailty and activation of the inflammation and coagulation
systems with and without clinical comorbidities: results from the Cardiovascular
Health Study. Arch Intern Med 2002;162:2333–2341.
14. Majumdar SR, Kim N, Colman I, Chahal AM, Raymond G, Jen H, Siminoski KG,
Hanley DA, Rowe BH. Incidental vertebral fractures discovered with chest radi-
ography in the emergency department: prevalence, recognition, and osteoporosis
management in a cohort of elderly patients. Arch Intern Med 2005;165:905–909.
15. Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Foody JM, Boden WE,
Smith SC Jr, Gibler WB, Ohman EM, Peterson ED. Evolution in cardiovascular
care for elderly patients with non-ST-segment elevation acute coronary syn-
dromes: results from the CRUSADE National Quality Improvement Initiative.
J Am Coll Cardiol 2005;46:1479–1487.
16. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW,
Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM,
Ohman EM. Acute coronary care in the elderly, part I: Non-ST-segment-elevation
acute coronary syndromes: a scientific statement for healthcare professionals
from the American Heart Association Council on Clinical Cardiology: in collab-
oration with the Society of Geriatric Cardiology. Circulation 2007;115:2549–2569.
17. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G.
Acute coronary syndromes without chest pain, an underdiagnosed and
undertreated high-risk group: insights from the Global Registry of Acute Coron-
ary Events. Chest 2004;126:461–469.
18. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classi-
fication, and stratification. Am J Kidney Dis 2002;39(2 Suppl. 1):S1–S266.
19. Tsutamoto T, Kawahara C, Yamaji M, Nishiyama K, Fujii M, Yamamoto T, Horie M.
Relationship between renal function and serum cardiac troponin T in patients
with chronic heart failure. Eur J Heart Fail 2009;11:653–658.
20. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, Eeckhout E,
Erne P, Estlinbaum W, Kuster G, Moccetti T, Naegeli B, Rickenbacher P. Outcome
of elderly patients with chronic symptomatic coronary artery disease with an
invasive vs optimized medical treatment strategy: one-year results of the random-
ized TIME trial. JAMA 2003;289:1117–1123.
21. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hos-
pitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:
1200–1205.
22. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly
patients. Br J Clin Pharmacol 2004;57:121–126.
23. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA,
Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H,
Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE,
Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO,
Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML,
Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR,
Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG,
Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V,
Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD,
McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL,
Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA,
Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N.
Universal definition of myocardial infarction. Circulation 2007;116:2634–2653.
24. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a
preliminary evaluation using a new troponin I assay with improved sensitivity.
Am J Clin Pathol 2007;128:282–286.
25. McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, Smith B,
Sharpe PC, Young IS, Adgey JA. Novel biomarkers in early diagnosis of acute myo-
cardial infarction compared with cardiac troponin T. Eur Heart J 2008;29:
2843–2850.
26. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical vali-
dation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254–261.
27. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or
more correlated receiver operating characteristic curves: a nonparametric
approach. Biometrics 1988;44:837–845.
28. Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, Scholer A,
Christ M, Perruchoud AP. Cost-effectiveness of B-type natriuretic peptide testing
in patients with acute dyspnea. Arch Intern Med 2006;166:1081–1087.
29. Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME,
Mueller-Brand J, Perruchoud AP, Mueller C. Use of B-type natriuretic peptide
in the detection of myocardial ischemia. Am Heart J 2006;151:1223–1230.
30. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA,
Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E. A sensitive
cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:
2538–2547.
Sensitive troponins for the early diagnosis of AMI 1389
